Gyre Therapeutics (GYRE) Research & Development (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Research & Development of $6.7 million for Q1 2026, up 117.71% year-over-year from $3.1 million in Q1 2025, and down 71.71% quarter-over-quarter from $23.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Research & Development (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Research & Development for 17 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 117.71% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $36.3 million (down 47.7% YoY), while the FY2025 annual figure was $65.2 million, up 13.33% from the prior year.
- Research & Development eased to $6.7 million in Q1 2026 per GYRE's latest filing, from $23.8 million in the prior quarter.
- Across five years, Research & Development topped out at $49.2 million in Q4 2024 and bottomed at -$30.9 million in Q4 2023.
- Historically, Research & Development has averaged $8.9 million across 5 years, with a median of $3.4 million in 2025.
- On a YoY basis, Research & Development climbed as much as 1634.5% in 2023 and fell as far as 173.85% in 2023.
- Gyre Therapeutics' Research & Development stood at $41.9 million in 2022, then plunged by 173.85% to -$30.9 million in 2023, then surged by 259.14% to $49.2 million in 2024, then sank by 51.59% to $23.8 million in 2025, then sank by 71.71% to $6.7 million in 2026.
- Business Quant data shows GYRE's Research & Development at $6.7 million in Q1 2026, $23.8 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 13.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.75 Mn |
| Mar 31, 2026 | 6.74 Mn |
| Dec 31, 2025 | 23.82 Mn |
| Sep 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.10 Mn |
| Dec 31, 2024 | 49.20 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 14.41 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Dec 31, 2023 | -30.92 Mn |
| Sep 30, 2023 | 13.93 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 41.86 Mn |
| Sep 30, 2022 | 803,000.00 |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 9.70 Mn |
| Dec 31, 2021 | -50.15 Mn |
| Sep 30, 2021 | 20.35 Mn |